The $31 Billion Question: Does the Pandemic Preparedness Maths Actually Hold Up? Australia, Beware!
The global pandemic-preparedness industry has a very large price tag attached to it, but remarkably little public discussion has focused on whether the economic calculations used to justify that expenditure actually make sense. The recent critique associated with David Bell and Ramesh Thakur (linked below), therefore deserves serious attention. The issue is not whether governments should prepare for infectious disease outbreaks. Of course they should. The issue is whether tens of billions of dollars should be redirected into a permanent international pandemic apparatus on the basis of assumptions that may exaggerate both the threat and the benefits supposedly produced by the proposed response.
The numbers themselves are enormous. A WHO–World Bank analysis prepared for the G20 in 2022 estimated annual pandemic prevention, preparedness and response requirements of approximately $31.1 billion. About $26.4 billion was attributed to country-level requirements, predominantly in low- and middle-income countries, with another $4.7 billion allocated to global and regional functions such as surveillance, research, manufacturing capacity and international coordination. After allowing for expenditure supposedly already being provided domestically and internationally, the analysis arrived at an additional international financing requirement of approximately $10.5 billion every year.
The argument has considerable political appeal. Spend billions now and prevent trillions in losses when the next pandemic arrives. Pandemic preparedness is consequently presented as a form of global insurance, with the potential return on investment sometimes described in extraordinary terms. If relatively modest annual expenditure could prevent another economic catastrophe on the scale associated with COVID-19, the investment would indeed seem compelling. The difficulty begins when the assumptions inside the economic models are examined rather than the headline numbers simply being accepted.
One of the most important criticisms concerns assumptions about mitigation. The economic case for pandemic preparedness can depend upon remarkably optimistic assumptions about how rapidly vaccines and other interventions could suppress a future pandemic and consequently prevent its economic costs. Yet the COVID experience should make us extremely cautious about assuming that a vaccine against a future respiratory pathogen will completely prevent transmission. The COVID vaccines did not eliminate transmission. There is an enormous difference between developing a useful vaccine and developing, manufacturing and distributing within months a vaccine capable of stopping a novel respiratory pathogen in its tracks. Economic models that approach the latter as an achievable baseline risk greatly exaggerating the return supposedly generated by preparedness expenditure.
An even deeper problem concerns the treatment of COVID's economic damage. The enormous economic losses of 2020 and subsequent years were not caused by the virus alone. They also reflected government responses to it: lockdowns, business closures, travel restrictions, school closures, emergency welfare expenditure, stimulus programs and massive disruptions to ordinary economic activity. Whatever one's judgment about whether particular measures were justified at the time, analytically these categories have to be separated. Disease costs and response costs are not the same thing.
This distinction is fundamental to any credible cost-benefit calculation. If a model takes the total economic losses experienced during COVID and treats them as the inevitable cost of a pandemic, it quietly converts political decisions into natural phenomena. Yet another pandemic need not produce precisely the same governmental response. Governments could decide that widespread lockdowns caused more damage than they prevented, that schools should remain open, that interventions should be concentrated upon vulnerable groups or that society should tolerate more transmission while protecting those at greatest risk. If so, much of the economic catastrophe used to justify enormous preparedness expenditure would not automatically recur. A model that counts the costs of lockdowns as pandemic costs while simultaneously treating future preparedness as the mechanism for avoiding those costs risks embedding the policy failures of the last pandemic into the justification for the next bureaucracy.
The comparison with existing global health problems is equally troubling. HIV/AIDS, tuberculosis, malaria, malnutrition and inadequate sanitation, continue to impose enormous and predictable burdens year after year. Malaria still kills hundreds of thousands annually, disproportionately affecting young children, while tuberculosis remains one of the world's major infectious killers. These are not hypothetical diseases that might appear at some unknown future date. Their victims are dying now, and the interventions required to reduce their burden are often well understood.
This brings us to the central economic concept that pandemic-preparedness advocacy too easily pushes into the background: opportunity cost. Governments do not possess unlimited health budgets. Money allocated to one objective cannot simultaneously be spent upon another. Billions devoted to elaborate surveillance networks, vaccine-development platforms, international bureaucracies and stockpiles are billions unavailable for nutrition programs, sanitation, clean drinking water, primary health care, childhood vaccination, malaria prevention, tuberculosis treatment and basic antibiotics.
That matters particularly in poorer countries, where relatively inexpensive improvements in nutrition, sanitation and primary medicine can produce enormous gains in healthy life expectancy. Historically, these mundane achievements have done much of the heavy lifting in reducing infectious-disease mortality. Better nutrition improves resistance to disease. Clean water and sanitation interrupt transmission. Antibiotics prevent secondary bacterial infections from turning otherwise survivable illnesses into fatal ones. Primary health systems identify and treat disease before it becomes catastrophic. None has the glamour of an international pandemic command structure, but global health should be concerned with lives saved rather than institutional glamour.
The Leeds work highlighted by critics of the present preparedness agenda raises precisely this proportionality problem. If pandemic preparedness absorbs something approaching a substantial fraction of existing global development assistance for health, governments need compelling evidence that it produces greater health benefits than competing uses of those resources. It is not sufficient to announce an enormous hypothetical future loss and then claim that almost any expenditure intended to prevent it represents excellent value. The probability of the event, the effectiveness of the intervention and the opportunity costs of expenditure all have to enter the calculation.
There is also an institutional problem that cannot simply be dismissed as conspiracy theory. Organisations respond to incentives. An international health organisation given greater responsibilities for pandemic preparedness gains funding, authority and institutional importance when pandemic risk is considered high. Universities and research institutes obtain grants for modelling, surveillance and pandemic research. Pharmaceutical and biotechnology companies benefit from vaccine development, countermeasure procurement and stockpiling. Public-private organisations involved in vaccine development and distribution acquire larger roles as governments allocate more resources to preparedness.
None of this proves dishonesty. People working within these organisations may sincerely believe that another catastrophic pandemic is imminent and that their programs represent the best means of preventing it. But conflicts of interest do not disappear merely because the people involved have good intentions. An institutional ecosystem in which almost every major participant benefits from higher estimates of pandemic risk has little internal incentive to conclude that the threat has been exaggerated or that the marginal billion dollars would save more lives if spent on tuberculosis, malaria, nutrition or sanitation.
COVID should have taught us to be especially suspicious of analyses in which the costs of intervention disappear from the ledger. Lockdowns had economic costs. School closures had educational and developmental costs. Deferred medical treatment had health costs. Business failures, unemployment and social isolation had human costs. Massive fiscal and monetary interventions had consequences that continued long after restrictions were lifted. A serious pandemic-preparedness model must count such effects rather than treating every government intervention as a costless mechanism for reducing infection.
There is also a broader historical question about proportionality. The twentieth and early twenty-first centuries saw extraordinary improvements in life expectancy despite the continued emergence of infectious diseases. Much of this progress resulted from sanitation, nutrition, antibiotics, vaccination, improved housing and increasingly sophisticated medical care. The 1918 influenza pandemic occurred in a radically different medical environment, before modern antibiotics, intensive care, contemporary diagnostic technology and today's general standard of health. That does not mean another devastating natural pandemic is impossible. It means that simply projecting historical catastrophes onto the modern world requires considerable caution.
COVID itself also produced a highly age-stratified mortality burden, with risk concentrated overwhelmingly among older and medically vulnerable people. That pattern matters when comparing pandemics with diseases such as malaria or conditions associated with childhood malnutrition, which can remove many decades of potential life from their victims. Counting deaths without considering age, disability, quality-adjusted life years or life years lost can produce profoundly misleading comparisons between health priorities.
For Australia, the appropriate conclusion is therefore neither panic nor complacency. Australia should maintain sensible infectious-disease surveillance, laboratory capability, medical stockpiles and contingency planning. What it should not do is sign blank cheques on the strength of economic models whose crucial assumptions have not survived adequate scrutiny. Before committing billions of taxpayer dollars to an expanding international preparedness architecture, governments should insist upon transparent cost-benefit analysis capable of independent replication.
That analysis should distinguish disease costs from the costs created by government responses. It should compare pandemic expenditure honestly with malaria, tuberculosis, HIV, malnutrition, sanitation and other competing health priorities. It should include the collateral damage caused by interventions such as prolonged lockdowns and school closures. It should avoid assuming that future vaccines will possess transmission-blocking capabilities for which there is no guarantee, and it should subject every major assumption about pandemic frequency, severity and mitigation to sensitivity analysis. Above all, the calculations should tell governments what happens when the optimistic assumptions fail.
This is ultimately what makes the Bell–Thakur criticism important. The question is not whether pandemics can be dangerous; history has already answered that. Nor is it whether preparation is worthwhile; reasonable preparation plainly is. The question is how much preparation is justified relative to all the other demands upon finite health resources, and whether the numbers being used to answer that question are credible.
A $31 billion annual requirement and a $10.5 billion international financing gap should not become accepted facts merely because they appear in documents bearing the logos of powerful international institutions. They are estimates produced by models, and models are only as reliable as their assumptions. If those assumptions confuse virus costs with lockdown costs, presume implausibly successful mitigation and neglect the lives that could be saved by spending the same money elsewhere, the resulting return on investment can become less an economic calculation than an exercise in institutional advocacy.
If the case for the emerging pandemic-preparedness architecture really is overwhelming, its proponents should welcome independent scrutiny of the numbers. They should publish the assumptions, expose the models to hostile testing and demonstrate that pandemic preparedness outperforms competing health investments under realistic scenarios rather than ideal ones. Australian taxpayers are entitled to nothing less.
Before Canberra commits further billions to the next global health emergency that has not yet happened, there is one entirely reasonable demand to make of the people presenting the bill: show us the actual mathematics, including the opportunity costs, rather than the marketing bs.
https://dailysceptic.org/2026/08/20/the-whos-high-price-pandemic-plan-is-built-on-smoke-and-mirrors/
